A digital ocular system includes a housing, an eye piece having a lens assembly. A display screen, a proximity sensor, and a processor. The lens assembly includes a front lens through which a user of the digital ocular system views a target object. The display screen is positioned within the housing cavity. The proximity sensor, which is connected to the housing, detects when user is within a predetermined standoff distance of the front lens, and outputs an electronic sensor signal when the user is outside of the predetermined standoff distance, i.e., not detected. The processor is configured to adjust an output state of the display screen via a display control signal in response to the electronic sensor signal.
Described herein are cyclic peptides targeting fibroblast activation protein (FAP), and their incorporation into compounds for radioligand imaging and therapies, as well as methods and/or uses of such compounds for the imaging, treatment and/or prevention of FAP-implicated diseases and disorders.
Korea Research Institute of Chemical Technology (Republic of Korea)
Inventor
Neyts, Johan
Poon, Daniel
Pfister, Keith Bruce
Jung, Young-Sik
Han, Soo Bong
Malpani, Yashwardhan R.
Chakrasali, Prashant
Lee, Sang-Ho
Lee, Chong-Kyo
Kim, Chonsaeng
Shin, Jin Soo
Kim, Hae Soo
Abstract
This disclosure provides compounds of Formula (I)
This disclosure provides compounds of Formula (I)
This disclosure provides compounds of Formula (I)
as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
C07D 307/93 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
9.
METHOD OF CORRECTING HIGHER-ORDER ABERRATIONS USING LASER VISION CORRECTION
The disclosure provides a method for correcting higher-order aberrations including providing a laser radiation. The method also includes controlling a location of a beam focal point of the laser radiation by a system of scanners and guiding the beam focal point in such a way that the location of the beam focal point is in a cornea of an eye. The method further includes introducing the laser radiation into the cornea of the eye. The method includes cutting a lenslet, wherein a thickness of the lenslet t(X,Y) satisfies a following equation: t(X,Y)=t0+Δt(X,Y)/(n−1), where Δt(X,Y) represents a higher-order wavefront elevation and t0 represents the thickness of the lenslet having a spherical refractive power of D.
The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an advanced moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).
A system for performing ophthalmic surgery includes a robotic positioning system including an end effector. The robotic positioning system is configured to position the end effector with at least five degrees of freedom. An ophthalmic surgical instrument is mounted to the end effector along with an accessory device configured to facilitate performance of an ophthalmic treatment by the ophthalmic surgical instrument. The robotic positioning system may be controlled to enforce anatomical boundaries and implement predefined motion profiles.
A system of visualizing a target site in an eye, using a polarization sensitive optical coherence tomography (PS-OCT) device, includes a controller having at least one processor and at least one non-transitory, tangible memory on which instructions are recorded. The target site is one or more vitreous opacities in the vitreous humor of the eye. The controller is configured to receive PS-OCT data and determine at least one parameter corresponding to birefringence properties of collagen fibrils in the vitreous humor based on the PS-OCT data. The at least one parameter includes respective spacing of the collagen fibrils. The controller is configured to determine a respective location of the one or more vitreous opacities when the at least one parameter is outside a predefined range and generate a control signal adapted for guiding a treatment beam at the respective location of the one or more vitreous opacities.
Certain aspects of the present disclosure provide systems and methods for measuring eye- tissue biomechanics via blink stimulation. In certain embodiments, a method may be performed by a computer in communication with an optical coherence tomography (OCT) device. The method includes monitoring movement relative to an eye of a patient via one or more images from a camera. The method also includes detecting a blink of the eye of the patient responsive to the monitoring. The method also includes, responsive to the detected blink, recording data resultant from a scan, by the OCT device, of at least a portion of a tissue of the eye. The method also includes measuring a tissue response to the detected blink based on the recorded data from the scan.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
14.
TAPERED OPTICAL FIBERS FOR SURGICAL INSTRUMENTATION
Embodiments disclosed herein relate to devices and systems for use in ophthalmic procedures. In some embodiments, a handpiece device for use with a surgical system is provided. The handpiece device includes a housing, a cable assembly, and a tapered optical fiber. The cable assembly is disposed through a distal end of the housing and optically coupled to the tapered optical fiber. The tapered optical fiber has a diameter that decreases between a proximal end of the tapered optical fiber and a distal end thereof. In some embodiments, the tapered optical fiber comprises a single-crystal fiber. In further embodiments, the tapered optical fiber comprises a tapered sapphire core fiber.
The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof;
The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof;
The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof;
wherein R1 R2, R4 and X1 are defined herein.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A lens drying system includes a sterile gas supply, a supply line, and an annular body. The body is connected to the supply line and defines an internal channel. The internal channel, which is in fluid communication with the sterile gas supply via the supply line, defines a plurality of openings. The openings are collectively configured to direct a flow of a sterile gas, e.g., a filtered and desiccated medical grade gas, from the sterile gas supply onto a lens surface of an ophthalmic front lens. This occurs during a non-contact wide-angle visualization process to mitigate fogging of the lens surface. A processor of a surgical console may receive user preference settings, including a desired steady-state flow rate and/or a desired pulse rate of the sterile gas. The processor could then command the desired steady-state flow rate and/or a desired pulse rate from the surgical console.
The invention relates to compounds which modulate the activity of ERK. The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by ERK.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
The present disclosure provides an intralocular-lens (IOL) or ophthalmic device including an optic and at least one haptic, at least a portion of which is formed from a photoresponsive shape memory polymer network, such as a polydomain azo liquid crystalline polymer network (PD-LCN). The present disclosure further provides systems and methods for adjusting the position of such an IOL or other ophthalmic device using polarized laser radiation.
A system for spatially binding images from multiple modalities includes a controller having at least one processor and at least one non-transitory, tangible memory. The controller is adapted to receive first and second imaging datasets of a target site from a first and a second modality. The controller is adapted to extract a first feature set in the first imaging dataset, via a first neural network. A second feature set is extracted from the second imaging dataset, via a second neural network. Feature pairs are generated by matching respective datapoints in the first feature set and the second feature set. The controller is adapted to determine a coordinate transformation between the feature pairs and generate at least one spatially bound image of the target site based in part on the coordinate transformation.
G06T 7/33 - Determination of transform parameters for the alignment of images, i.e. image registration using feature-based methods
G06V 10/75 - Organisation of the matching processes, e.g. simultaneous or sequential comparisons of image or video featuresCoarse-fine approaches, e.g. multi-scale approachesImage or video pattern matchingProximity measures in feature spaces using context analysisSelection of dictionaries
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
21.
TLR7/8-ANTAGONIST FOR TREATING SJÖGREN'S SYNDROME OR MIXED CONNECTIVE TISSUE DISEASE
The present disclosure relates to methods for treating Sjögren's Syndrome or mixed connective tissue disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Sjögren's Syndrome or mixed connective tissue disease patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
A system of visualizing a target site in an eye, using a polarization sensitive optical coherence tomography (PS-OCT) device, includes a controller having at least one processor and at least one non-transitory, tangible memory on which instructions are recorded. The target site is one or more vitreous opacities in the vitreous humor of the eye. The controller is configured to receive PS-OCT data and determine at least one parameter corresponding to birefringence properties of collagen fibrils in the vitreous humor based on the PS-OCT data. The at least one parameter includes respective spacing of the collagen fibrils. The controller is configured to determine a respective location of the one or more vitreous opacities when the at least one parameter is outside a predefined range and generate a control signal adapted for guiding a treatment beam at the respective location of the one or more vitreous opacities.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
G02B 27/28 - Optical systems or apparatus not provided for by any of the groups , for polarising
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Ophthalmic viewing systems for visualizing structures on and in an eye of a medical patient include an ophthalmic microscope, a gonioscopy device configured to work with the ophthalmic microscope to provide an image of an interior of the patient's eye, and a robotic arm configured to hold the gonioscopy device in a position in relation to the ophthalmic microscope and the patient's eye to provide the image of the eye's interior.
A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/103 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining refraction, e.g. refractometers, skiascopes
Provided herein are compounds and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are compounds which are inhibitors of SARS-CoV-2 main protease (Mpro), pharmaceutical compositions comprising such compounds, method for synthesizing such compounds and methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
Ophthalmic viewing systems for visualizing structures on and in an eye of a medical patient include an ophthalmic microscope, a gonioscopy device configured to work with the ophthalmic microscope to provide an image of an interior of the patient's eye, and a robotic arm configured to hold the gonioscopy device in a position in relation to the ophthalmic microscope and the patient's eye to provide the image of the eye's interior.
A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
A digital ocular system includes a housing, an eye piece having a lens assembly. A display screen, a proximity sensor, and a processor. The lens assembly includes a front lens through which a user of the digital ocular system views a target object. The display screen is positioned within the housing cavity. The proximity sensor, which is connected to the housing, detects when user is within a predetermined standoff distance of the front lens, and outputs an electronic sensor signal when the user is outside of the predetermined standoff distance, i.e., not detected. The processor is configured to adjust an output state of the display screen via a display control signal in response to the electronic sensor signal.
Embodiments disclosed herein provide an optical fiber system. The optical fiber system includes an aspiration tube, an optical fiber external to the aspiration tube, and a sleeve surrounding the optical fiber and the aspiration tube. The sleeve includes a distal portion that defines a channel. The channel extends between the aspiration tube and a distal opening of the sleeve. The channel and the aspiration tube define an aspiration pathway. The optical fiber is partially disposed within the channel.
A system for spatially binding images from multiple modalities includes a controller having at least one processor and at least one non-transitory, tangible memory. The controller is adapted to receive first and second imaging datasets of a target site from a first and a second modality. The controller is adapted to extract a first feature set in the first imaging dataset, via a first neural network. A second feature set is extracted from the second imaging dataset, via a second neural network. Feature pairs are generated by matching respective datapoints in the first feature set and the second feature set. The controller is adapted to determine a coordinate transformation between the feature pairs and generate at least one spatially bound image of the target site based in part on the coordinate transformation.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 40/18 - Eye characteristics, e.g. of the iris
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
29.
LASER ALIGNMENT SYSTEM AND A METHOD FOR LASER ALIGNMENT
The present disclosure generally relates to systems and methods for laser alignment, and more particularly, systems and methods for alignment of an optical element for laser transmission. In certain embodiments, a cover plate is configured to slide into place on an optic mounting plate. Positioning the cover plate applies force to a biasing element to press an optical element against a registration surface of the optic mounting plate to align the optical element with an optical aperture. The cover plate may be secured relative to the optic mounting plate to retain the biasing element and the optical element.
The present disclosure relates to the field of pharmacy, particularly to an NLRP3 inhibitor for use in the treatment of osteoarthritis. The disclosure also relates to an NLRP3 inhibitor or a pharmaceutical combination comprising an NLRP3 inhibitor, and at least one further therapeutic agent, for use in the treatment of osteoarthritis; to a method for the treatment of osteoarthritis that involves administering an NLRP3 inhibitor or the combination; and to the use of an NLRP3 inhibitor or the combination for the manufacture of a medicament for the treatment of osteoarthritis.
The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Embodiments disclosed herein provide an optical fiber system. The optical fiber system includes an aspiration tube, an optical fiber external to the aspiration tube, and a sleeve surrounding the optical fiber and the aspiration tube. The sleeve includes a distal portion that defines a channel. The channel extends between the aspiration tube and a distal opening of the sleeve. The channel and the aspiration tube define an aspiration pathway. The optical fiber is partially disposed within the channel.
The present disclosure generally relates to systems and methods for laser alignment, and more particularly, systems and methods for alignment of an optical element for laser transmission. In certain embodiments, a cover plate is configured to slide into place on an optic mounting plate. Positioning the cover plate applies force to a biasing element to press an optical element against a registration surface of the optic mounting plate to align the optical element with an optical aperture. The cover plate may be secured relative to the optic mounting plate to retain the biasing element and the optical element.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
In certain embodiments, an ophthalmic lens includes an optic having an anterior surface, a posterior surface, and an optical axis. At least one of the anterior surface and the posterior surface includes a first zone extending from the optical axis to a first radial boundary and a second zone extending from the first radial boundary to the edge of the optic. The first zone includes an inner region and an outer region separated by a phase shift feature, the phase shift comprising a ridge extending outwardly from the inner region and the outer region.
The present disclosure relates generally to systems and processes for assessing and differentiating asthma and chronic obstructive pulmonary disease (COPD) in a patient, and more specifically to computer-based systems and processes for providing a predicted diagnosis of asthma and/or COPD. In accordance with one or more examples, a computing system receives a set of patient data corresponding to a first patient and determines whether the set of patient data satisfies a set of one or more data-correlation criteria. If the set of one or more data-correlation criteria are satisfied, the computing system applies a first diagnostic model to the set of patient data and determines a first predicted diagnosis of asthma and/or COPD. If the set of one or more data-correlation criteria are not satisfied, the computing system applies a second diagnostic model to the set of patient data and determines a second predicted diagnosis of asthma and/or COPD.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
39.
SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO OR MORE POLYLACTIDE-CO-GLYCOLIDE POLYMERS
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-coglycolide polymers (PLGAS).
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
40.
COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Embodiments disclosed herein relate to devices and systems for use in ophthalmic procedures. In some embodiments, a handpiece device for use with a surgical system is provided. The handpiece device includes a housing, a cable assembly, and a tapered optical fiber. The cable assembly is disposed through a distal end of the housing and optically coupled to the tapered optical fiber. The tapered optical fiber has a diameter that decreases between a proximal end of the tapered optical fiber and a distal end thereof. In some embodiments, the tapered optical fiber comprises a single-crystal fiber. In further embodiments, the tapered optical fiber comprises a tapered sapphire core fiber.
A61F 9/008 - Methods or devices for eye surgery using laser
A61B 17/00 - Surgical instruments, devices or methods
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/22 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor
42.
MEASURING EYE-TISSUE BIOMECHANICS VIA BLINK STIMULATION
Certain aspects of the present disclosure provide systems and methods for measuring eye-tissue biomechanics via blink stimulation. In certain embodiments, a method may be performed by a computer in communication with an optical coherence tomography (OCT) device. The method includes monitoring movement relative to an eye of a patient via one or more images from a camera. The method also includes detecting a blink of the eye of the patient responsive to the monitoring. The method also includes, responsive to the detected blink, recording data resultant from a scan, by the OCT device, of at least a portion of a tissue of the eye. The method also includes measuring a tissue response to the detected blink based on the recorded data from the scan.
A system for performing ophthalmic surgery includes a robotic positioning system including an end effector. The robotic positioning system is configured to position the end effector with at least five degrees of freedom. An ophthalmic surgical instrument is mounted to the end effector along with an accessory device configured to facilitate performance of an ophthalmic treatment by the ophthalmic surgical instrument. The robotic positioning system may be controlled to enforce anatomical boundaries and implement predefined motion profiles.
Systems and methods for tracking the position and condition of an eye during an ophthalmic procedure include an ophthalmic device configured to measure characteristics of an eye, an eye tracker configured to capture a stream of eye images, and a logic device configured to analyze the stream of images to determine whether the eye is fixating on a target object, detect a predetermined blink sequence in the first stream of images, delay for a predetermined tear stabilization period, start a stable tear film interval, and during the stable tear film interval, capture at least one measurement of the eye using the ophthalmic device when the eye is fixating. The blink sequence may include a plurality of blinks in succession and the detection of the blink sequence may include processing the images through a neural network trained to detect an open eye and/or a closed eye.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/14 - Arrangements specially adapted for eye photography
Systems, methods, and computer-readable media for integrating and optimizing a surgical suite. An ophthalmic suite can include a surgical console, a heads-up display communicatively coupled with a surgical camera for capturing a three-dimensional image of an eye, and a surgical suite optimization engine. The surgical suite optimization engine can performs a wide variety of actions in response to action codes received from the other components in the surgical suite. The surgical suite optimization engine can be integrated within another component of the surgical suite, can be a stand-alone module, and can be a cloud-based tool.
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 17/00 - Surgical instruments, devices or methods
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/98 - Identification means for patients or instruments, e.g. tags using electromagnetic means, e.g. transponders
A61F 9/008 - Methods or devices for eye surgery using laser
The present invention concerns a dosage form, preferably for immediate release, comprising siponimod, a moisture-protective-agent and further pharmaceutical excipients and methods for producing said dosage form.
An optical coherence tomography (OCT) scanning system for measuring ocular tissue characteristics of a patient's eye. The system includes an OCT scanner configured to implement a scanning sequence on the ocular tissue that scans the ocular tissue with an optical signal to obtain OCT data based on a reflected version of the optical signal. The system includes a computer with a processor configured to provide control signals to the OCT scanner to implement the scanning sequence, and to determine a rate of change of the phase or amplitude data associated with the scans. The system determines a growth constant of the reflected version of the optical signal based on the rate of change of the phase or amplitude data, and determines, based on the growth constant, a diffusion coefficient associated with the cornea. The system determines, based on the diffusion coefficient, a quantitative parameter of the cornea.
In certain embodiments, a surgical handpiece system includes a phacoemulsification tip, a fluid management system, an ultrasonic drive system, and a controller. The phacoemulsification tip is attached to a shaft. The fluid management system is configured to manage inflow and outflow of fluid from an ocular surgical site. The ultrasonic drive system is configured to generate torsional and longitudinal vibrations in the phacoemulsification tip. The controller is configured to analyze applied voltage and current to the ultrasonic drive system using Fast Fourier Transforms (FFTs), and tune applied frequencies of the torsional and longitudinal vibrations according to at least one resonant frequency.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
Described herein is a system for surgical procedures. The system can include a tray and a wireless remote. The tray may include a magnetically attractive layer. The wireless remote is configured to control one or more aspects associated with operations of a surgical console and includes one or more magnets configured to magnetically interact with the magnetically attractive layer and couple the wireless remote to the tray.
A system includes an actuator, one or more items of diagnostic equipment configured to perform ophthalmic measurement, and one or more items of treatment equipment configured to facilitate performance of an ophthalmic treatment with respect to an eye of a patient. A controller is coupled to the actuator and is configured to cause the actuator to transfer the one or more items of diagnostic equipment and the one or more items of treatment equipment into and out of a region in front of an eye of the patient. The ophthalmic treatment may be a LASIK or SMILE treatment using refractive error and/or eye geometry measured using the diagnostic equipment.
A61F 9/008 - Methods or devices for eye surgery using laser
A61B 3/103 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining refraction, e.g. refractometers, skiascopes
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
51.
MEASURING BIOMECHANICS IN REAL TIME AT MULTIPLE EYE-TISSUE LOCATIONS
Certain aspects of the present disclosure provide systems and methods for measuring biomechanics in real-time at multiple eye-tissue locations. In certain embodiments, a method may be performed by a computer in communication with an optical coherence tomography (OCT) device. The method includes receiving an indication of a stimulus applied to eye tissue of a patient. The method also includes instructing the OCT device to emit a plurality of beams, at approximately the same time, to a plurality of measurement locations on the eye tissue in response to the received indication. The method also includes receiving, from the OCT device, OCT data for each of the plurality of measurement locations. The method also includes measuring tissue responses to the stimulus at the plurality of measurement locations based on the OCT data.
Described herein are methods of treating gMG (generalized Myasthenia gravis) with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt or hydrate thereof.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Described herein include a system and method for a device for drug delivery and ophthalmic diagnostics designed to assist in the diagnosis of the physical state of a cornea through the projection of droplets onto the eye. In some embodiments, the apparatus includes a liquid sampling unit, an electric droplet generator, and a steering unit. In some embodiments, the liquid sampling unit is configured to project a quantity of liquid, while the electric droplet generator receives the quantity of liquid and outputs one or more electrically charged droplets. The steering unit uses electrostatic forces to steer the electrically charged droplets along a trajectory onto the cornea of the patient's eye.
A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 15/02 - Inhalators with activated or ionized gasesOzone-inhalators
B05B 17/06 - Apparatus for spraying or atomising liquids or other fluent materials, not covered by any other group of this subclass operating with special methods using ultrasonic vibrations
54.
DEVICE AND METHOD FOR MEASURING OCULAR TISSUE CHARACTERISTICS
An optical coherence tomography (OCT) scanning system for measuring ocular tissue characteristics of a patient's eye. The system includes an OCT scanner configured to implement a scanning sequence on the ocular tissue that scans the ocular tissue with an optical signal to obtain OCT data based on a reflected version of the optical signal. The system includes a computer with a processor configured to provide control signals to the OCT scanner to implement the scanning sequence, and to determine a rate of change of the phase or amplitude data associated with the scans. The system determines a growth constant of the reflected version of the optical signal based on the rate of change of the phase or amplitude data, and determines, based on the growth constant, a diffusion coefficient associated with the cornea. The system determines, based on the diffusion coefficient, a quantitative parameter of the cornea.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/107 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining the shape or measuring the curvature of the cornea
55.
SYSTEM AND METHOD FOR A SURGICAL HANDPIECE AND MULTI-MODAL TIP
In certain embodiments, a surgical handpiece system includes a phacoemulsification tip, a fluid management system, an ultrasonic drive system, and a controller. The phacoemulsification tip is attached to a shaft. The fluid management system is configured to manage inflow and outflow of fluid from an ocular surgical site. The ultrasonic drive system is configured to generate torsional and longitudinal vibrations in the phacoemulsification tip. The controller is configured to analyze applied voltage and current to the ultrasonic drive system using Fast Fourier Transforms (FFTs), and tune applied frequencies of the torsional and longitudinal vibrations according to at least one resonant frequency.
The present disclosure generally relates to port connector assemblies for delivering infusion gases during ophthalmic surgeries and procedures. In some embodiments, the connector assembly includes a connector for a surgical console and a corresponding receiver for connecting the connector to the surgical console.
A61M 39/12 - Tube connectors or tube couplings for joining a flexible tube to a rigid attachment
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
57.
SYSTEM AND METHOD FOR PERFORMING OPHTHALMIC LASER ASSISTED SURGERY WITH IMMERSION LIQUIDS
Disclosed herein is a method of performing ophthalmic surgery. The surgery includes positioning a patient interface relative to a patient's eye with the patient interface at least partially defining an interface chamber with the patient's eye. The interface chamber is filled with an immersion fluid. A fluid in an anterior chamber of the patient's eye is replaced with the immersion fluid, wherein the immersion fluid matches the refractive index of the cornea. A laser system is positioned relative to the patient interface. The laser system includes a laser source configured to generate a femtosecond laser beam and an optical delivery and scanner system in communication with the laser source to direct 3D scanned and focused laser beams through the patient interface and into the patient's eye.
A system includes an actuator, one or more items of diagnostic equipment configured to perform ophthalmic measurement, and one or more items of treatment equipment configured to facilitate performance of an ophthalmic treatment with respect to an eye of a patient. A controller is coupled to the actuator and is configured to cause the actuator to transfer the one or more items of diagnostic equipment and the one or more items of treatment equipment into and out of a region in front of an eye of the patient. The ophthalmic treatment may be a LASIK or SMILE treatment using refractive error and/or eye geometry measured using the diagnostic equipment.
Certain aspects of the present disclosure provide systems (10) and methods (800) for measuring biomechanics in real-time at multiple eye-tissue locations. In certain embodiments, a method (800) may be performed by a computer (30) in communication with an optical coherence tomography, OCT, device (15, 315). The method includes receiving an indication of a stimulus applied to eye tissue (346) of a patient (42). The method also includes instructing the OCT device (15, 315) to emit a plurality of beams (344, 560, 660), at approximately the same time, to a plurality of measurement locations (772) on the eye tissue (346) in response to the received indication. The method (800) also includes receiving, from the OCT device (15, 315), OCT data for each of the plurality of measurement locations (772). The method (800) also includes measuring tissue responses to the stimulus at the plurality of measurement locations based on the OCT data.
A system for performing ophthalmic treatments includes a handpiece configured to be held by a hand of a surgeon. An end effector is mounted to the handpiece and configured to manipulate tissue of a patient, such tissues of the eye when performing an ophthalmic treatment. The system includes a motion sensor configured to sense movement of the handpiece and one or more stabilizing actuators configured to stabilize movement of the handpiece in response to movement of the hand of the surgeon. A controller is coupled to the motion sensor and the one or more stabilizing actuators and is configured to instruct the one or more stabilizing actuators to compensate for motion detected by the motion sensor. The controller may include a high-pass filer with the output of the high-pass filter used to control the stabilizing actuators. The parameters of the high pass filter may be adjusted throughout an ophthalmic treatment.
Described herein include a system and method for a device for drug delivery and ophthalmic diagnostics designed to assist in the diagnosis of the physical state of a cornea through the projection of droplets onto the eye. In some embodiments, the apparatus includes a liquid sampling unit, an electric droplet generator, and a steering unit. In some embodiments, the liquid sampling unit is configured to project a quantity of liquid, while the electric droplet generator receives the quantity of liquid and outputs one or more electrically charged droplets. The steering unit uses electrostatic forces to steer the electrically charged droplets along a trajectory onto the cornea of the patient's eye.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
62.
SYSTEM AND METHOD FOR PERFORMING OPHTHALMIC LASER ASSISTED SURGERY WITH IMMERSION LIQUIDS
Disclosed herein is a method of performing ophthalmic surgery. The surgery includes positioning a patient interface relative to a patient's eye with the patient interface at least partially defining an interface chamber with the patient's eye. The interface chamber is filled with an immersion fluid. A fluid in an anterior chamber of the patient's eye is replaced with the immersion fluid, wherein the immersion fluid matches the refractive index of the cornea. A laser system is positioned relative to the patient interface. The laser system includes a laser source configured to generate a femtosecond laser beam and an optical delivery and scanner system in communication with the laser source to direct 3D scanned and focused laser beams through the patient interface and into the patient's eye.
The present disclosure generally relates to port connector assemblies for delivering infusion gases during ophthalmic surgeries and procedures. In some embodiments, the connector assembly includes a connector for a surgical console and a corresponding receiver for connecting the connector to the surgical console.
Systems and methods for measuring corneal biomechanical properties are provided. In certain embodiments, a method comprises determining a plurality of optical coherence tomography (OCT) measurement locations in a region of a cornea; for each OCT measurement location: applying a mechanical excitation to the cornea at the OCT measurement location, and measuring a response of the cornea to the mechanical excitation by acquiring temporal OCT data at the OCT measurement location; generating temporal deformation data for the region of the cornea based on the temporal OCT data at each OCT measurement location; and generating biomechanical data for the region of the cornea based on the temporal deformation data.
A system and method for corneal cross-linking with real-time monitoring are provided. The method comprises determining a plurality of measurement locations in a region of a cornea, and applying a corneal cross-linking treatment to the region of the cornea. During the application of the corneal cross-linking treatment, the method also comprises acquiring a temporal OCT interferogram at each OCT measurement location, generating temporal complex OCT data based on the temporal OCT interferogram, determining biomechanical data based on the temporal complex OCT data, and adjusting the corneal cross-linking treatment based on the biomechanical data.
A system includes an actuator, one or more items of diagnostic equipment configured to perform ophthalmic measurement, and one or more items of treatment equipment configured to facilitate performance of an ophthalmic treatment with respect to an eye of a patient. A controller is coupled to the actuator and is configured to cause the actuator to transfer the one or more items of diagnostic equipment and the one or more items of treatment equipment into and out of a region in front of an eye of the patient. The ophthalmic treatment may be a LASIK or SMILE treatment using refractive error and/or eye geometry measured using the diagnostic equipment.
A system for performing ophthalmic treatments includes a handpiece configured to be held by a hand of a surgeon. An end effector is mounted to the handpiece and configured to manipulate tissue of a patient, such tissues of the eye when performing an ophthalmic treatment. The system includes a motion sensor configured to sense movement of the handpiece and one or more stabilizing actuators configured to stabilize movement of the handpiece in response to movement of the hand of the surgeon. A controller is coupled to the motion sensor and the one or more stabilizing actuators and is configured to instruct the one or more stabilizing actuators to compensate for motion detected by the motion sensor. The controller may include a high-pass filer with the output of the high-pass filter used to control the stabilizing actuators. The parameters of the high pass filter may be adjusted throughout an ophthalmic treatment.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
Described herein is a system for surgical procedures. The system can include a tray and a wireless remote. The tray may include a magnetically attractive layer. The wireless remote is configured to control one or more aspects associated with operations of a surgical console and includes one or more magnets configured to magnetically interact with the magnetically attractive layer and couple the wireless remote to the tray.
Systems and methods for measuring corneal biomechanical properties are provided. In certain embodiments, a method comprises determining a plurality of optical coherence tomography (OCT) measurement locations in a region of a cornea; for each OCT measurement location: applying a mechanical excitation to the cornea at the OCT measurement location, and measuring a response of the cornea to the mechanical excitation by acquiring temporal OCT data at the OCT measurement location; generating temporal deformation data for the region of the cornea based on the temporal OCT data at each OCT measurement location; and generating biomechanical data for the region of the cornea based on the temporal deformation data.
A system and method for corneal cross-linking with real-time monitoring are provided. The method comprises determining a plurality of measurement locations in a region of a cornea, and applying a corneal cross-linking treatment to the region of the cornea. During the application of the corneal cross-linking treatment, the method also comprises acquiring a temporal OCT interferogram at each OCT measurement location, generating temporal complex OCT data based on the temporal OCT interferogram, determining biomechanical data based on the temporal complex OCT data, and adjusting the corneal cross-linking treatment based on the biomechanical data.
A system includes an actuator, one or more items of diagnostic equipment configured to perform ophthalmic measurement, and one or more items of treatment equipment configured to facilitate performance of an ophthalmic treatment with respect to an eye of a patient. A controller is coupled to the actuator and is configured to cause the actuator to transfer the one or more items of diagnostic equipment and the one or more items of treatment equipment into and out of a region in front of an eye of the patient. The ophthalmic treatment may be a LASIK or SMILE treatment using refractive error and/or eye geometry measured using the diagnostic equipment.
The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoetic stem cells in a patient in need thereof.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
73.
MEANS AND METHOD FOR PREPARING VIRAL VECTORS AND USES OF SAME
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
74.
INTRA-OPERATIVE VISUALIZATION, MEASUREMENT, AND ASSISTANCE FOR OPHTHALMIC TREATMENTS
A system for performing ophthalmic treatments includes a surgical microscope configured to capture surface images of an eye of a patient and an imaging device mounted to the surgical microscope and configured to capture section images of the eye of the patient. A controller is coupled to the surgical microscope and the imaging device, the controller configured to receive the surface images and section images and provide feedback facilitating performance of the ophthalmic treatments based on the section images and the surface images. Feedback may relate to avoiding bag rupture during phacoemulsification, safely performing retinal membrane peeling, placing an IOL, treating glaucoma, or performing other ophthalmic treatments.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A system for performing ophthalmic treatments includes a surgical microscope configured to capture surface images of an eye of a patient and an imaging device mounted to the surgical microscope and configured to capture section images of the eye of the patient. A controller is coupled to the surgical microscope and the imaging device, the controller configured to receive the surface images and section images and provide feedback facilitating performance of the ophthalmic treatments based on the section images and the surface images. Feedback may relate to avoiding bag rupture during phacoemulsification, safely performing retinal membrane peeling, placing an IOL, treating glaucoma, or performing other ophthalmic treatments.
The present disclosure relates to methods for treating non-radiographic axial spondyloarthritis (nr-axSpA) patients and inhibiting the progression of structural damage in these patients, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating nr-axSpA patients and inhibiting the progression of structural damage in these patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent, and/or diagnose cancerous or infectious conditions and disorders.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I),
The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I),
The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I),
wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
An ophthalmic assembly includes a frame, flange, and light emitter. The frame supports an optical lens. A first end of the flange is connected to the frame. A second end of the flange rests on a pars plana region of the sclera of a patient's eye. The light emitter is connected to the flange proximate the second end to direct light into a vitreous cavity of the patient's eye. This occurs through the sclera at the pars plana region and uniformly illuminates the vitreous. A transscleral illumination system includes the ophthalmic assembly and a processor in communication with the light emitter. A setting of the light emitter may be controllable via the processor, e.g., in response to a user input signal.
A method and system provide an ophthalmic device. The ophthalmic device includes an ophthalmic lens having an anterior surface, a posterior surface, at least one diffractive structure and at least one base curvature. The at least one diffractive structure for provides a first spherical aberration for a first focus corresponding to at least a first focal length. The at least one base curvature provides a second spherical aberration for at least a second focus corresponding to at least a second focal length. The first spherical aberration and the second spherical aberration are provided such that the first focus has a first focus spherical aberration and the second focus has a second focus spherical aberration. The first focus spherical aberration is opposite in sign to the second focus spherical aberration.
Disclosed are adjustable accommodating intraocular lenses and methods of adjusting accommodating intraocular lenses post-operatively. In one embodiment, an adjustable accommodating intraocular lens comprises an optic portion and a peripheral portion. At least one of the optic portion and the peripheral portion can be made in part of a composite material comprising an energy absorbing constituent and a plurality of expandable components. At least one of a base power and a cylindricity of the optic portion can be configured to change in response to an external energy directed at the composite material.
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
A61L 27/50 - Materials characterised by their function or physical properties
83.
COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK
The invention relates to compounds which modulate the activity of ERK. The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by ERK.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Systems and methods for performing robotic surgery are provided. The system may include a robotic manipulator having a working end coupled to a base by a plurality of joints and links, a surgical tool having a tool portion and a connector portion coupled to the working end of the robotic manipulator, and a control system having a tool interface operable to communicate with the surgical tool, a robotic manipulator interface communicatively coupled to the robotic manipulator, and a processor coupled to the tool interface and the robotic manipulator interface. The processor may be configured to receive data from the surgical tool and control the robotic manipulator based on the data received from the surgical tool. The method may include receiving data from a surgical tool connected to a working end of a robotic manipulator and controlling the robotic manipulator based on the data received from the surgical tool.
A61B 90/98 - Identification means for patients or instruments, e.g. tags using electromagnetic means, e.g. transponders
A61F 9/008 - Methods or devices for eye surgery using laser
A61B 17/00 - Surgical instruments, devices or methods
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
Systems and methods for performing robotic surgery are provided. The system may include a robotic manipulator having a working end coupled to a base by a plurality of joints and links, a surgical tool having a tool portion and a connector portion coupled to the working end of the robotic manipulator, and a control system having a tool interface operable to communicate with the surgical tool, a robotic manipulator interface communicatively coupled to the robotic manipulator, and a processor coupled to the tool interface and the robotic manipulator interface. The processor may be configured to receive data from the surgical tool and control the robotic manipulator based on the data received from the surgical tool. The method may include receiving data from a surgical tool connected to a working end of a robotic manipulator and controlling the robotic manipulator based on the data received from the surgical tool.
A61B 17/00 - Surgical instruments, devices or methods
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/98 - Identification means for patients or instruments, e.g. tags using electromagnetic means, e.g. transponders
The present invention generally relates to inherently wettable silicone hydrogel contact lenses having relatively high oxygen permeability, relatively high equilibrium water content and relatively low elastic modulus. The present invention is also related to a method for making such inherently wettable silicone hydrogel contact lenses.
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
C08G 77/12 - Polysiloxanes containing silicon bound to hydrogen
C08G 77/14 - Polysiloxanes containing silicon bound to oxygen-containing groups
C08G 77/20 - Polysiloxanes containing silicon bound to unsaturated aliphatic groups
C08G 77/388 - Polysiloxanes modified by chemical after-treatment containing atoms other than carbon, hydrogen, oxygen or silicon containing nitrogen
C08G 77/392 - Polysiloxanes modified by chemical after-treatment containing atoms other than carbon, hydrogen, oxygen or silicon containing sulfur
C08L 83/10 - Block- or graft-copolymers containing polysiloxane sequences
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
A system and method quantify light exposure of a patient's retina during an ophthalmic procedure. A light source illuminates the patient's retina with directed light during the procedure to produce an illuminated retina surface. A camera collects image data of the illuminated retina surface. An electronic control unit (ECU) in communication with the camera and an indicator device receives the image data, calculates a cumulative energy spectral density of the directed light falling incident upon the retina, and executes a control action indicative of possible light toxicity in response to the cumulative energy spectral density exceeding a light toxicity threshold, including activating the indicator device. The illuminated retina surface may be divided into virtual zones, with the ECU mapping the cumulative energy spectral density to the illuminated retina surface. Each of the optional zones has a corresponding cumulative energy spectral density.
The present disclosure generally relates to surgical instruments having variable stiffness, and more particularly, surgical instruments having variable stiffness for ophthalmic surgical procedures. In certain embodiments, a surgical instrument includes a base unit, a probe, a stiffener, and an actuation mechanism. The stiffener is formed of a hollow tubular member substantially surrounding at least a portion of a length of the probe. The actuation mechanism is configured to actuate the stiffener along the length of the probe and adjust the stiffness of the probe, thus providing a user better control of the surgical instrument. The actuation mechanism includes a stiffener biasing device configured to apply a first biasing force against the stiffener in the distal direction and, in some embodiments, a control member configured to lock the stiffener in a position along the length of the probe.
Particular embodiments disclosed herein provide a surgical instrument comprising a device having a proximal end and a functional end configured to be inserted into a body part, an assembly having a proximal end and a distal end, a shaft coupled to the proximal end of the assembly, the shaft having a shaft housing, a bearing positioned around the assembly, wherein the bearing is configured to slide over the assembly, a hub having a sleeve tube. The basket comprises a plurality of grooved levers, each grooved lever having a proximal end received by the shaft housing and a distal end coupled to a tip of the basket, wherein compressing one or more of the plurality of grooved levers moves the bearing and the hub relative to the shaft and toward the functional end of the device, causing the sleeve tube to transition the device from the deactivated state to an activated state.
Described herein are cyclic peptides targeting fibroblast activation protein (FAP), and their incorporation into compounds for radioligand imaging and therapies, as well as methods and/or uses of such compounds for the imaging, treatment and/or prevention of FAP-implicated diseases and disorders.
An ophthalmic assembly includes a frame, flange, and light emitter. The frame supports an optical lens. A first end of the flange is connected to the frame. A second end of the flange rests on a pars plana region of the sclera of a patient's eye. The light emitter is connected to the flange proximate the second end to direct light into a vitreous cavity of the patient's eye. This occurs through the sclera at the pars plana region and uniformly illuminates the vitreous. A transscleral illumination system includes the ophthalmic assembly and a processor in communication with the light emitter. A setting of the light emitter may be controllable via the processor, e.g., in response to a user input signal.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
A61F 9/009 - Auxiliary devices for making contact with the eyeball and coupling-in laser light
A61B 3/14 - Arrangements specially adapted for eye photography
Described herein is a UV/HEVL-filtering SiHy contact lens that not only has a relatively high UV/HEVL filtering capability but also has an aesthetic appealing color. The bulk silicone hydrogel of the UV/HEVL-filtering SiHy contact lens comprises repeating units of (1) at least one hydrophilic vinylic monomer, (2) at least one siloxane-containing vinylic monomer and/or at least one polysiloxane vinylic crosslinker, (3) at least one UV-absorbing vinylic monomer, and (4) a least one polymerizable HEVL-absorbing compound capable of absorbing HEVL between 380 nm and 450 nm and also comprises at least one blue-tinting agent and at least one optical brightener distributed therein.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
A method, instructions for which are executed from a computer-readable medium, calibrates a robotic camera system having a digital camera connected to an end-effector of a serial robot. The end-effector and camera move within a robot motion coordinate frame (“robot frame”). The method includes acquiring, using the camera, a reference image of a target object on an image plane having an optical coordinate frame, and receiving input signals, including a depth measurement and joint position signals. Separate roll and pitch offsets are determined of a target point within the reference image with respect to the robot frame while moving the robot. Offsets are also determined with respect to x, y, and z axes of the robot frame while moving the robot through another motion sequence. The offsets are stored in a transformation matrix, which is used to control the robot during subsequent operation of the camera system.
The present invention relates to Tapinarof dimethylacetamide solvate and crystalline forms thereof, processes for preparation and pharmaceutical compositions thereof. Furthermore, the invention concerns its use for the preparation of a medicament, preferably for the treatment of skin diseases.
C07C 39/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing only six-membered aromatic rings as cyclic part, with unsaturation outside the rings with at least one hydroxy group on a non-condensed ring
C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
Described herein is a UV/HEVL-filtering SiHy contact lens that not only has a relatively high UV/HEVL filtering capability but also has an aesthetic appealing color. The bulk silicone hydrogel of the UV/HEVL-filtering SiHy contact lens comprises repeating units of (1) at least one hydrophilic vinylic monomer, (2) at least one siloxane-containing vinylic monomer and/or at least one polysiloxane vinylic crosslinker, (3) at least one UV-absorbing vinylic monomer, and (4) a least one polymerizable HEVL-absorbing compound capable of absorbing HEVL between 380 nm and 450 nm and also comprises at least one blue-tinting agent and at least one optical brightener distributed therein.
